EditCo is excited to attend and sponsor the 9th COREdinates Annual Meeting, bringing together leaders in stem cell research, cell therapy, and disease modeling.
At EditCo, we specialize in high-quality, CRISPR-engineered iPSC lines designed to support robust, reproducible research, from early discovery to translational applications. Our solutions are built to be rapid, precise, scalable, and high-value, helping researchers generate physiologically relevant models with confidence.
Visit us to learn how EditCo’s automated CRISPR platform and cell engineering expertise can support:
-
CRISPR-edited Knockout iPS Cells using XDel™ technology
-
CRISPR-edited Knock-in iPS Cells with HiBiT protein tagging for precise endogenous reporting
- High-quality iPSC disease models for functional genomics and translational research
We look forward to connecting with the COREdinates community and discussing how engineered iPSC lines can accelerate your research.
Let’s connect at COREdinates 2026!
Download iPSC tech note:
Precision CRISPR Editing of Induced Pluripotent Stem (iPS) Cells
Read More in EDITorial:
Ensuring iPSC Quality: Best Practices in Pluripotency Testing for Disease Models
Check Out Case Study:
Industrialized CRISPR iPS Cells Enable NIH Large Scale Alzheimer’s Disease Research Effort
Publications using EditCo (formerly Synthego) CRISPR iPSCs:
- Small molecules restore mutant mitochondrial DNA polymerase activity. Valenzuela S et al. Nature (2025)
- Visualizing PIEZO1 Localization and Activity in hiPSC-Derived Single Cells and Organoids with HaloTag Technology. Bertaccini GA et al. Nature Communications (2025)
- TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy. Alquezar C et al. Science Advances (2021)
Reserve your spot by filling out the form below!